Reduced apoptosis after nerve growth factor and serum withdrawal: Conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer

Molecular Pharmacology

Volumn 57, Issue 1, 2000, Pages 2-12

  Carlile, Graeme W ^a   Chalmers Redman, Ruth M E ^a   Tatton, Nadine A ^a   Pong, Amanda ^a   Borden, Katherine E ^a   Tatton, William G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DIMER; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOLYTIC ENZYME; MONOAMINE OXIDASE B INHIBITOR; N METHYL N PROPARGYL 10 AMINOMETHYL DIBENZO[B,F]OXEPIN; NERVE GROWTH FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE; NORSELEGILINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RNA; SELEGILINE; TETRAMER; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL LYSATE; CONTROLLED STUDY; ENZYME LOCALIZATION; ENZYME STRUCTURE; GLYCOLYSIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; RAT; SERUM;

AMPHETAMINES; ANIMALS; APOPTOSIS; BLOOD PROTEINS; DIMERIZATION; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; MONOAMINE OXIDASE INHIBITORS; NERVE GROWTH FACTOR; OXEPINS; PC12 CELLS; PROTEIN CONFORMATION; RATS; SELEGILINE;

EID: 0033989493     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Ansari KS, Yu PH, Kruck TP and Tatton WG. (1993) Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: Stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 13:4042-4053.
2. Borden KL (1998) Structure/function in neuroprotection and apoptosis. Ann Neurol 44:S65-S71.
3. Borden KL, Campbell Dwyer EJ, Carlile GW, Djavani M and Salvato MS (1998) Two ring finger proteins, the ocoprotein PMB and the arenavirus protein Z associate with the ribosomal P-proteins. J Virol 72:3819-3826.
4. Burke JR, Enghild JJ, Martin ME, Jou YS, Myers RM, Roses AD, Vance JM and Strittmatter WJ (1996) Huntington and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med 2:347-350.
5. Carlile GW, Tatton WG and Borden KLB (1998) Demonstration of a RNA-dependent nuclear interaction between the promelocytic leukaemia protein and glyceraldehyde-3-phosphate dehydrogenase. Biochem J 335:691-696.
6. Cotman CW (1998) Apoptosis decision cascades and neuronal degeneration in Alzheimer's disease. Neurobiol Aging 19:S29-S32.
7. Fahn S (1996) Controversies in the therapy of Parkinson's disease. Adv Neurol 69:477-486.
8. Heinonen EH, Anttila MI, Karnani HL, Nyman LM, Vuorinen JA, Pyykko KA and Lammintausta RA (1997) Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. J Clin Pharmacol 37:602-509.
9. Ishitani R, Sunaga K, Hirano A, Saunders P, Katsube N and Chuang DM (1996) Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J Neurochem 66:928-935.
10. +-induced apoptosis but not necrosis of cultured cerebellar granule cells. Mol Pharmacol 51:542-550.
11. Ishitani R, Tanaka M, Sunaga K, Katsube N and Chuang DM (1998) Nuclear localization of overexpressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons undergoing apoptosis. Mol Pharmacol 53:701-707.
12. Karoum F, Chuang LW, Eisler T, Calne DB, Liebowitz MR, Quitkin FM, Klein DF and Wyatt RJ (1982) Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: A biochemical assessment. Neurology 32:503-509.
13. Kim H, Feil IK, Verlinde CL, Petra PH and Hol WG (1995) Crystal structure of glycosomal glyceraldehyde-3-phosphate dehydrogenase from Leiskmania mexicana: Implications for structure-based drug design and a new position for the inorganic phosphate binding site. Biochemistry 34:14975-14986.
14. Kish SJ, Lopes-Cendes I, Guttman M, Furukawa Y, Pandolfo M, Rouleau GA, Ross BM, Nance M, Schut L, Ang L and DiStefano L (1998) Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders. Arch Neurol 55:1299-1304.
15. Kragten E, Lalande I, Zimmermann K, Roggo S, Schindler P, Muller D, van Oostrum J, Waldmeier P and Furst P (1998) Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem 273:5821-5828.
16. Le W, Jankovic J, Xie W, Kong R and Appel SH (1997) (-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition. Neurosci Lett 224:197-200.
17. Magyar K, Szende B, Lengyel J, Tarczali J and Szatmary I (1998) The neuroprotective and neuronal rescue effects of (-)-deprenyl. J Neural Transm Suppl 52:109-123.
18. Maruyama W, Takahashi T and Naoi M (1998) (-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J Neurochem 70:2510-2515.
19. Melnick A and Licht JD (1999) Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167-3215.
20. Minton AP and Wilf J (1981) Effect of macromolecular crowding upon the structure and function of an enzyme: Glyceraldehyde-3-phosphate dehydrogenase. Biochemistry 20:4821-4826.
21. Nagy E and Rigby WF (1995) Glyceraldehyde-3-phosphate dehydrogenase selectively binds AU-rich RNA in the NAD(+)-binding region (Rossmann fold). J Biol Chem 270:2755-2763.
22. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D and Esterlitz J (1995) The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 38:771-777.
23. Parkinson's Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328:176-183.
24. Patel SV, Tariot PN and Asnis J (1996) L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease. Ann Clin Psychiatry 8:23-26.
25. Paterson IA, Barber AJ, Gelowitz DL and Voll C (1997) (-)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Neurosci Biobehav Rev 21:181-186.
26. Paterson IA, Zhang D, Warrington RC and Boulton AA (1998) R-Deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium. J Neurochem 70:515-523.
27. Petersen A, Mani K and Brundin P (1999) Recent advances on the pathogenesis of Huntington's disease. Exp Neurol 157:1-18.
28. Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B (1997) A model for p53-induced apoptosis [see comments]. Nature (Lond) 389:300-305.
29. Ronai Z (1993) Glycolytic enzymes as DNA binding proteins. Int J Biochem 25:1073-1076.
30. Saunders PA, Chalecka-Franaszek E and Chuang DM (1997) Subcellular distribution of glyceraldehyde-3-phosphate dehydrogenase in cerebellar granule cells undergoing cytosine arabinoside-induced apoptosis. J Neurochem 69:1820-1828.
31. Sawa A, Khan AA, Hester LD and Snyder SH (1997) Glyceraldehyde-3-phosphate dehydrogenase: Nuclear translocation participates in neuronal and nonneuronal cell death. Proc Nat Acad Sci USA 94:11669-11674.
32. Schulzer M, Mak E and Calne DB (1992) The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic [see comments]. Ann Neurol 32:795-798.
33. Shashidharan P, Chalmers-Redman RM, Carlile GW, Rodic V, Gurvich N, Yuen T, Tatton WG and Sealfon SC (1999) Nuclear translocation of GAPDH-GFP fusion protein during apoptosis. Neuroreport 10:1149-1153.
34. Sioud M and Jespersen L (1996) Enhancement of hammerhead ribozyme catalysis by glyceraldehyde-3-phosphate dehydrogenase. J Mol Biol 257:775-789.
35. Sirover MA (1997) Role of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in normal cell function and in cell pathology. J Cell Biochem 66:133-140.
36. Sunaga K, Takahashi H, Chuang DM and Ishitani R (1995) Glyceraldehyde-3-phosphate dehydrogenase is over-expressed during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaques from Alzheimer's brain. Neurosci Lett 200:133-136.
37. Tatton NA, Maclean-Fraser A, Tatton WG, Perl DP and Olanow CW (1998) A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol 44:S142-S148.
38. Tatton WG and Chalmers-Redman RM (1996) Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controling neurodegeneration. Neurology 47:S171-S183.
39. Tatton WG, Ju WY, Holland DP, Tai C and Kwan M (1994) (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63:1572-1575.
40. Wadia JS, Chalmers-Redman RME, Ju WJH, Carlile GW, Phillips JL, Fraser AD and Tatton WG (1998) Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: Time course and modification by (-)-deprenyl. J Neurosci 18:932-947.
41. Zimmermann K, Roggo S, Kragten E, Furst P and Waldmeier P (1998) Synthesis of tools for target identification of the anti-apoptotic compound CGP 3466: Part I. Bioorg Med Chem Let 8:1195-1200.